Single User License
INR 96000
Site License
INR 192000
Corporate User License
INR 288000

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Vical Incorporated-Product Pipeline Review-2015

Vical Incorporated-Product Pipeline Review-2015

  • Products Id :- GMDHC07301CDB
  • |
  • Pages: 34
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Vical Incorporated-Product Pipeline Review-2015


Global Markets Direct's, 'Vical Incorporated-Product Pipeline Review-2015', provides an overview of the Vical Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Vical Incorporated including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Vical Incorporated's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Vical Incorporated's pipeline products

Reasons To Buy

Evaluate Vical Incorporated's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Vical Incorporated in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Vical Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Vical Incorporated and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vical Incorporated

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Vical Incorporated Snapshot 5

Vical Incorporated Overview 5

Key Information 5

Key Facts 5

Vical Incorporated-Research and Development Overview 6

Key Therapeutic Areas 6

Vical Incorporated-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products-Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Vical Incorporated-Pipeline Products Glance 14

Vical Incorporated-Clinical Stage Pipeline Products 14

Phase I Products/Combination Treatment Modalities 14

Vical Incorporated-Early Stage Pipeline Products 15

IND/CTA Filed Products/Combination Treatment Modalities 15

Preclinical Products/Combination Treatment Modalities 16

Vical Incorporated-Drug Profiles 17

VCLHB-01 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

VCLHM-01 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

CyMVectin 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

ASP-2397 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

measles (bivalent) vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Vical Incorporated-Pipeline Analysis 22

Vical Incorporated-Pipeline Products by Target 22

Vical Incorporated-Pipeline Products by Route of Administration 23

Vical Incorporated-Pipeline Products by Molecule Type 24

Vical Incorporated-Recent Pipeline Updates 25

Vical Incorporated-Dormant Projects 28

Vical Incorporated-Discontinued Pipeline Products 29

Discontinued Pipeline Product Profiles 29

HIV Vaccine 29

Vical Incorporated-Company Statement 30

Vical Incorporated-Locations And Subsidiaries 32

Head Office 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

Vical Incorporated, Key Information 5

Vical Incorporated, Key Facts 5

Vical Incorporated-Pipeline by Indication, 2015 7

Vical Incorporated-Pipeline by Stage of Development, 2015 8

Vical Incorporated-Monotherapy Products in Pipeline, 2015 9

Vical Incorporated-Partnered Products in Pipeline, 2015 10

Vical Incorporated-Partnered Products/ Combination Treatment Modalities, 2015 11

Vical Incorporated-Out-Licensed Products in Pipeline, 2015 12

Vical Incorporated-Out-Licensed Products/ Combination Treatment Modalities, 2015 13

Vical Incorporated-Phase I, 2015 14

Vical Incorporated-IND/CTA Filed, 2015 15

Vical Incorporated-Preclinical, 2015 16

Vical Incorporated-Pipeline by Target, 2015 22

Vical Incorporated-Pipeline by Route of Administration, 2015 23

Vical Incorporated-Pipeline by Molecule Type, 2015 24

Vical Incorporated-Recent Pipeline Updates, 2015 25

Vical Incorporated-Dormant Developmental Projects,2015 28

Vical Incorporated-Discontinued Pipeline Products, 2015 29

List of Figures

Vical Incorporated-Pipeline by Top 10 Indication, 2015 7

Vical Incorporated-Pipeline by Stage of Development, 2015 8

Vical Incorporated-Monotherapy Products in Pipeline, 2015 9

Vical Incorporated-Partnered Products in Pipeline, 2015 10

Vical Incorporated-Pipeline by Top 10 Target, 2015 22

Vical Incorporated-Pipeline by Top 10 Molecule Type, 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Vical Incorporated; Vical Incorporated - Key Therapeutics; Vical Incorporated - Pipeline Overview and Promising Molecules; Vical Incorporated - News; Vical Incorporated - Latest Updates; Vical Incorporated - Pipeline; Vical Incorporated - Discontinued/Dormant Projects

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]